With positive Phase 1 results for the metabolic disorder drug MZE782, Maze Therapeutics plans to advance the small molecule to Phase 2 tests in phenylketonuria and chronic kidney disease. Following the data readout, Maze raised $150 million in a private placement.
The post Maze Therapeutics Drug Shows Potential to Top Asset Acquired by Otsuka for $800M appeared first on MedCity News.
What’s Next for Walgreens Following its Private Equity Sale?
Walgreens has completed its sale to private equity firm Sycamore Partners, raising concerns that the deal could lead to widespread store closures, layoffs and reduced
